WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

The patent landscape for biologics, biosimilars, and advanced therapeutic antibodies is undergoing rapid change, presenting both opportunities and challenges for innovators and manufacturers. This panel will explore current issues and strategies in this dynamic field.

Key topics include:

Patent eligibility considerations for biologics and antibodies

The BPCIA patent dance and its implications

Navigating patent thickets in the biologics space

Strategies for prosecuting bispecific antibody patent applications around the world

Addressing novelty and non-obviousness challenges

Navigating different jurisdictional approaches

Balancing broad protection with sufficient disclosure

Strategies for overcoming rejections specific to bispecific antibodies

Comparative analysis of prosecution strategies in key markets (US, Europe, China, Japan)

Emerging trends in biologic and antibody patenting